Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?

Aimovig
Whether pent-up demand for new migraine drug Aimovig will translate to high sales is a burning question for Amgen investors. (Amgen)

Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that by handing out a lot of the product for free. But are they having trouble switching those patients to full-paying customers, courtesy of their insurers, and how will that affect the ultimate market potential of the drug?

That was the prevailing concern during Amgen’s second-quarter earnings call on Thursday evening, and judging from the tenor of the questions analysts asked, the company hasn’t quite eased investors’ fears.

“Right now, the majority of our business is in free drug, but we are rapidly converting that business to paid prescriptions,” said Anthony Hooper, Amgen’s executive vice president of global commercial operations. Hooper, whose retirement was announced along with earnings, didn’t offer many details about how that transition is progressing.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Fact is, Amgen needs to get payers on board with Aimovig—and fast. Even though the biotech giant and partner Novartis boasted first-mover advantage in the new class of migraine drugs known as CGRP inhibitors, they won’t own the market for long. Eli Lilly, Teva and Allergan are in late-stage development of their CGRP drugs, with Lilly and Teva expecting FDA decisions in September.

RELATED: Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig: expert

Reports of payer pushback on Aimovig emerged just before Amgen’s earnings call. Several Blue Cross plans told Reuters they’re only approving coverage of the drug when the prescriptions come with the blessing of a specialist who is certified by the United Council for Neurologic Subspecialties, and only a tiny percentage of neurologists are in that group. Other payers require preauthorization, proof that patients have tried older, less expensive therapies, or other information that can be a hassle for physicians to provide. 

Hooper reminded analysts during the earnings call that Amgen set up a patient hub to provide two months' worth of Aimovig for free while it completed negotiations with insurers. The company also has a “bridging program,” he said, to provide even more drug if patients can’t get their insurance companies on board before the end of the two-month period. Amgen has succeeded in attaining coverage for almost 30% of covered patients so far, he said.

Hooper reported that Amgen “received a large bolus of requests from the Headache Centers of Excellence reflecting the pent-up demand for this innovative new therapy.” But when pressed by analysts to define the size of the bolus so they could predict the revenue impact, Hooper declined to elaborate.

“We're trying to make sure that we understand how unique each of those patients are, coming in, and that they are appropriate patients. I would say that, as you watch the evolution of the prescriptions coming out of that, you'll start getting a feel of the size of the bolus,” he said.

One analyst asked Hooper to look beyond the bolus and to predict how important primary care physicians will be in driving the growth of Aimovig. Hooper admitted there are only 20 headache specialty centers in the U.S. and “another couple of thousand neurologists” who could also be prescribers. “But I do believe that the role of primary care physicians down the road becomes important. They do see patients and their ability to refer patients who are appropriate for a drug like Aimovig would be critical for the long-term value of this drug,” he said.

RELATED: Ex-BMS commercial head Gordon lands at Amgen amid exec shuffle

Aimovig fears overshadowed what was otherwise a solid quarter for Amgen. The company’s revenues of $6.06 billion beat estimates by 3% and its earnings per share of $3.83 came in 33 cents higher than expected, driven by better-than-expected performance of older products like Prolia for osteoporosis and Sensipar to treat hyperparathyroidism.

Still, the pressure on the company to move beyond its older hit products and forge into more lucrative markets was evident, not just in the Aimovig discussion during the earnings call but also in the C-suite shakeup. Hooper is being replaced by Murdo Gordon, chief commercial officer of Bristol-Myers Squibb. And Amgen’s R&D chief, Sean Harper, M.D., is also retiring. He’ll be replaced by David M. Reese, M.D., Amgen’s senior vice president of translational sciences and oncology, the company said.

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.